Moving Beyond Bispecifics with Multivalent T cell Engagers in Solid Tumors
Time: 1:30 pm
day: Day Two
Details:
- ModeX’s multispecific antibody platform technology designed for syngergistic targeting and streamlined manufacturing in a single product
- The pathway from design, creation, and characterization to the clinic
- Utilizing information about validated targets and known immune mechanisms to characterize clinical safety and efficacy in patients with advanced solid tumors
